Clinical outcomes by low baseline and 4-month biomarker levels. The lower the S100A8/9 or S100A12 levels at baseline, the higher the likelihood of achieving JIA-ACR ID and JIA-ACR100 at months 4 and 16 (Supplementary Table 3). The gene discussed is S100A8; the disease is juvenile idiopathic arthritis.